Sector Chart Gilead Sciences, Inc. Sao Paulo

Equities

Delayed Sao Paulo Other stock markets 20:45:20 11/06/2024 BST			5-day change	1st Jan Change
173.2 ^BRL	-0.43%		+4.05%	-10.01%

06-10	Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer	MT
06-06	Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes